AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32548877 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-generated candidate beams
Number of subjects: 0
Study 32548877 — intervention group
Group type: COMPARATOR
Intervention: Heuristic candidate beams
Number of subjects: 0
Study 34977994 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacy practice model
Number of subjects: 5
Study 34977994 — intervention group
Group type: COMPARATOR
Intervention: Usual care process (Control)
Number of subjects: 5
Study 33354815 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg intravenous subdissociative ketamine (low dose)
Number of subjects: 98
Study 33354815 — intervention group
Group type: COMPARATOR
Intervention: 0.30 mg/kg intravenous subdissociative ketamine (high dose)
Number of subjects: 98
Study 33354815 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 98
Study 35280748 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-course enteral nutrition management
Number of subjects: 222
Study 35280748 — intervention group
Group type: COMPARATOR
Intervention: Unsystematic nutrition without setting intake goals for energy and protein
Number of subjects: 222
Study 32267168 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Number of subjects: 35
Study 32267168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy
Number of subjects: 35
Study 32267168 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 35
Study 36180944 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver transplantation (LT) + best established treatment (BET)
Number of subjects: 0
Study 36180944 — intervention group
Group type: COMPARATOR
Intervention: Best established treatment (BET) only
Number of subjects: 0
Study 33842832 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 289
Study 33842832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 32840891 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based Genomic Nursing Education Intervention
Number of subjects: 0
Study 32840891 — intervention group
Group type: COMPARATOR
Intervention: Standard web-based nursing education (Control)
Number of subjects: 0
Study 35015083 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dinner timing (4 hours prior to habitual bedtime)
Number of subjects: 845
Study 35015083 — intervention group
Group type: COMPARATOR
Intervention: Late dinner timing (1 hour prior to habitual bedtime)
Number of subjects: 845
Study 33058886 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC-ESD (spring-and-loop with clip traction-assisted endoscopic submucosal dissection)
Number of subjects: 80
Study 33058886 — intervention group
Group type: COMPARATOR
Intervention: C-ESD (conventional endoscopic submucosal dissection)
Number of subjects: 80
Study 32064640 — intervention group
Group type: EXPERIMENTAL
Intervention: Karydakis technique (KT)
Number of subjects: 58
Study 32064640 — intervention group
Group type: COMPARATOR
Intervention: PE/laser ablation technique (PE + LAT)
Number of subjects: 58
Study 35925708 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Trauma Recovery for Refugees (MBTR-R)
Number of subjects: 158
Study 35925708 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 158
Study 33432790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 86
Study 33432790 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 86
Study 34624138 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol and d-chiro-inositol combination (MI + DCI) 550 + 150 mg, twice a day for 6 months
Number of subjects: 70
Study 34624138 — intervention group
Group type: COMPARATOR
Intervention: Combined hormonal contraceptive (CHC) (ethinyl estradiol 20 µg + drospirenone 3 mg), once a day for 6 months
Number of subjects: 70
Study 34310202 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT plus AS (Androgen Suppression)
Number of subjects: 481
Study 34310202 — intervention group
Group type: COMPARATOR
Intervention: EBRT (Control)
Number of subjects: 481
Study 34310202 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT plus AS
Number of subjects: 481
Study 32703216 — intervention group
Group type: EXPERIMENTAL
Intervention: AA mixture containing 1.8 g of arginine, 1.1 g of valine, and 0.1 g of serine
Number of subjects: 20
Study 32703216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32271637 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral isotretinoin alone at a dose of 0.3 mg/kg/day
Number of subjects: 108
Study 32271637 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida antigen alone at a dose of 0.1 ml of 1/1000 solution into the largest wart
Number of subjects: 108
Study 32271637 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Candida antigen and oral isotretinoin by the same method and dose
Number of subjects: 108
Study 32621325 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix (oral gonadotropin-releasing hormone antagonist)
Number of subjects: 0
Study 32621325 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix (various doses)
Number of subjects: 0
Study 33187759 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone treatment plus patient navigation (IM + PN)
Number of subjects: 225
Study 33187759 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone treatment (IM)
Number of subjects: 225
Study 33187759 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Treatment-as-Usual (ETAU)
Number of subjects: 225
Study 33187759 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 225
Study 35679902 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 30
Study 35679902 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 30
Study 35679902 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined HA and PRP
Number of subjects: 30
Study 35679902 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (HA, PRP, HA+PRP)
Number of subjects: 30
Study 34409891 — intervention group
Group type: EXPERIMENTAL
Intervention: HAD-B1 (972 mg)
Number of subjects: 14
Study 34409891 — intervention group
Group type: EXPERIMENTAL
Intervention: HAD-B1 (1944 mg)
Number of subjects: 14
Study 34409891 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 14
Study 34465477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 147
Study 34465477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 34668596 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril-valsartan
Number of subjects: 376
Study 34668596 — intervention group
Group type: COMPARATOR
Intervention: enalapril
Number of subjects: 376
Study 32246262 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meals (beef, pork, chicken) consumed by healthy volunteers in the RCT
Number of subjects: 0
Study 32246262 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with high or moderate protein levels followed by overweight participants in the PREVIEW study
Number of subjects: 0
Study 32246262 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of biomarkers including carnosine
Number of subjects: 0
Study 32870712 — intervention group
Group type: EXPERIMENTAL
Intervention: Minodronate
Number of subjects: 3896
Study 32870712 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene
Number of subjects: 3896
Study 35679949 — intervention group
Group type: EXPERIMENTAL
Intervention: CDED+PEN
Number of subjects: 80
Study 35679949 — intervention group
Group type: COMPARATOR
Intervention: EEN
Number of subjects: 80
Study 33667228 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self-rated health (SRH)
Number of subjects: 350
Study 33667228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate self-rated health (SRH)
Number of subjects: 350
Study 33667228 — intervention group
Group type: COMPARATOR
Intervention: High self-rated health (SRH)
Number of subjects: 350
Study 33667228 — intervention group
Group type: COMPARATOR
Intervention: Self-rated health (SRH)
Number of subjects: 350
Study 36162887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT) with diode laser (980 nm, 100 mW for 1 minute)
Number of subjects: 30
Study 36162887 — intervention group
Group type: COMPARATOR
Intervention: Placebo LLLT (Control group)
Number of subjects: 30
Study 36162887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 30
Study 32996020 — intervention group
Group type: EXPERIMENTAL
Intervention: Mutation-positive patients (ATM, CHEK2, PALB2)
Number of subjects: 145
Study 35716046 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin pretreatment
Number of subjects: 1192
Study 35716046 — intervention group
Group type: COMPARATOR
Intervention: No statin pretreatment
Number of subjects: 1192
Study 33986125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab administered immediately after sipuleucel-T
Number of subjects: 50
Study 33986125 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab administered delayed 3 weeks after sipuleucel-T
Number of subjects: 50
Study 33986125 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of sipuleucel-T and ipilimumab
Number of subjects: 50
Study 33986125 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior localized radiation therapy (RT)
Number of subjects: 50
Study 35815700 — intervention group
Group type: EXPERIMENTAL
Intervention: Likert scoring
Number of subjects: 791
Study 35815700 — intervention group
Group type: COMPARATOR
Intervention: PI-RADS scoring
Number of subjects: 791
Study 35815700 — intervention group
Group type: EXPERIMENTAL
Intervention: Likert tool
Number of subjects: 791
Study 34535469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 13157
Study 34535469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13157
Study 34969423 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention using behavioural counselling with nicotine replacement therapy (NRT) gum
Number of subjects: 100
Study 34969423 — intervention group
Group type: COMPARATOR
Intervention: Behavioural counselling alone
Number of subjects: 100
Study 32448164 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Inspiration Breath-Hold (DIBH) technique
Number of subjects: 210
Study 32448164 — intervention group
Group type: COMPARATOR
Intervention: Free Breathing (FB) technique
Number of subjects: 210
Study 32448164 — intervention group
Group type: EXPERIMENTAL
Intervention: DIBH-RT for non-smokers
Number of subjects: 210
Study 32448164 — intervention group
Group type: EXPERIMENTAL
Intervention: DIBH-RT for smokers
Number of subjects: 210
Study 35956334 — intervention group
Group type: EXPERIMENTAL
Intervention: Omija extract and soybean mixture (OSM)
Number of subjects: 80
Study 35956334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 34444773 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower oil (SFO)
Number of subjects: 23
Study 34444773 — intervention group
Group type: COMPARATOR
Intervention: Heavy cream (HC)
Number of subjects: 23
Study 34444773 — intervention group
Group type: COMPARATOR
Intervention: Fish oil (FO)
Number of subjects: 23
Study 34444773 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (OO)
Number of subjects: 23
Study 34444773 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FSO)
Number of subjects: 23
Study 34444773 — intervention group
Group type: EXPERIMENTAL
Intervention: All fat sources
Number of subjects: 23
Study 33900154 — intervention group
Group type: EXPERIMENTAL
Intervention: High FIS and trained therapists
Number of subjects: 45
Study 33900154 — intervention group
Group type: COMPARATOR
Intervention: Low FIS and untrained therapists
Number of subjects: 45
Study 33318118 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention including 'Stop and Watch' early warning tool, condition-specific care pathway, and communication enhancement tools.
Number of subjects: 245
Study 33318118 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention
Number of subjects: 245
Study 36128612 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered Behavioral Activation with Mental Imagery (BA-MI)
Number of subjects: 38
Study 34836276 — intervention group
Group type: EXPERIMENTAL
Intervention: High avocado allotment (14/week/family)
Number of subjects: 72
Study 34836276 — intervention group
Group type: COMPARATOR
Intervention: Low avocado allotment (3/week/family)
Number of subjects: 72
Study 32030887 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily until disease progression
Number of subjects: 9
Study 36128694 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFETY-A
Number of subjects: 105
Study 36128694 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 105
Study 33428640 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles Supplementary Immunization Activity (SIA)
Number of subjects: 476
Study 32756160 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 32756160 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 35433551 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral guidance intervention
Number of subjects: 99
Study 35433551 — intervention group
Group type: COMPARATOR
Intervention: Routine pediatric care
Number of subjects: 99
Study 33404637 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily)
Number of subjects: 190
Study 33404637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 35089218 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg daily before contrast agent and hydration
Number of subjects: 202
Study 35089218 — intervention group
Group type: COMPARATOR
Intervention: Hydration only (Control)
Number of subjects: 202
Study 35089218 — intervention group
Group type: EXPERIMENTAL
Intervention: Febuxostat combined with hydration
Number of subjects: 202
Study 32824920 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 8
Study 32824920 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 8
Study 35527585 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-ctDCS + task-oriented training
Number of subjects: 16
Study 35527585 — intervention group
Group type: COMPARATOR
Intervention: Sham-ctDCS + task-oriented training
Number of subjects: 16
Study 33685500 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvianolate 200 mg intravenously dripped for 30 min and then for 7 days
Number of subjects: 78
Study 33685500 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% normal saline)
Number of subjects: 78
Study 33685500 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvianolate 200 mg
Number of subjects: 78
Study 33120356 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐minute ice massage prior to iontophoresis treatment
Number of subjects: 24
Study 33120356 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment ice massage (control group)
Number of subjects: 24
Study 33895362 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed budesonide-formoterol (BUD-FORM) 200/6 μg
Number of subjects: 0
Study 33895362 — intervention group
Group type: COMPARATOR
Intervention: BUD maintenance 200 μg
Number of subjects: 0
Study 33895362 — intervention group
Group type: COMPARATOR
Intervention: As-needed terbutaline 0.5 mg
Number of subjects: 0
Study 32589686 — intervention group
Group type: EXPERIMENTAL
Intervention: 3xDNA plus 1xNYVAC (weeks 0, 4, 8 plus 24; n = 74)
Number of subjects: 147
Study 32589686 — intervention group
Group type: COMPARATOR
Intervention: 2xDNA plus 2xNYVAC (weeks 0, 4 plus 20, 24; n = 73)
Number of subjects: 147
Study 34864483 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based mobile application (experimental group)
Number of subjects: 154
Study 34864483 — intervention group
Group type: COMPARATOR
Intervention: No additional intervention (control group)
Number of subjects: 154
Study 34304234 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen 30 mg/kg with IV placebo
Number of subjects: 66
Study 34304234 — intervention group
Group type: COMPARATOR
Intervention: IV acetaminophen 15 mg/kg with oral placebo
Number of subjects: 66
Study 34304234 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetaminophen
Number of subjects: 66
Study 34304234 — intervention group
Group type: COMPARATOR
Intervention: IV acetaminophen
Number of subjects: 66
Study 35613801 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous microwave ablation (EMA)
Number of subjects: 180
Study 35613801 — intervention group
Group type: COMPARATOR
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 180
Study 33475414 — intervention group
Group type: EXPERIMENTAL
Intervention: Sepsis leaflet
Number of subjects: 585
Study 33475414 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional vaccination leaflet
Number of subjects: 585
Study 33475414 — intervention group
Group type: COMPARATOR
Intervention: Control leaflet
Number of subjects: 585
Study 32197291 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic disease (asthma)
Number of subjects: 1468033
Study 32197291 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic disease (atopic dermatitis)
Number of subjects: 1468033
Study 32197291 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic disease (allergic rhinitis)
Number of subjects: 1468033
Study 34654038 — intervention group
Group type: EXPERIMENTAL
Intervention: Desk + Program
Number of subjects: 95
Study 34654038 — intervention group
Group type: EXPERIMENTAL
Intervention: Desk Only
Number of subjects: 95
Study 34654038 — intervention group
Group type: EXPERIMENTAL
Intervention: Program Only
Number of subjects: 95
Study 34654038 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 95
Study 34008756 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-gene signature (CBX7, JADE2, IGF2BP3, OR2W6P, PRAME, TICRR, KIF4A, and PIMREG)
Number of subjects: 0
Study 34008756 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-gene signature
Number of subjects: 0
Study 32690730 — intervention group
Group type: EXPERIMENTAL
Intervention: Not using drugs
Number of subjects: 425
Study 32690730 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower psychological distress
Number of subjects: 425
Study 32690730 — intervention group
Group type: EXPERIMENTAL
Intervention: Good mental health scores
Number of subjects: 425
Study 32690730 — intervention group
Group type: EXPERIMENTAL
Intervention: Better physical health
Number of subjects: 425
Study 34438327 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin deficiency diet (1.48 mg riboflavin/kg)
Number of subjects: 40
Study 34438327 — intervention group
Group type: COMPARATOR
Intervention: Control diet (16.48 mg riboflavin/kg)
Number of subjects: 40
Study 32958820 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin) plus erlotinib
Number of subjects: 352
Study 32958820 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin)
Number of subjects: 352
Study 32958820 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin) plus erlotinib
Number of subjects: 352
Study 32958820 — intervention group
Group type: COMPARATOR
Intervention: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy (paclitaxel and cisplatin)
Number of subjects: 352
Study 35236727 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Number of subjects: 281
Study 35236727 — intervention group
Group type: COMPARATOR
Intervention: Usual care wait list control
Number of subjects: 281
Study 33338463 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ultrasound-guided subacromial injections (40 mg triamcinolone acetonide)
Number of subjects: 60
Study 33338463 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-target injections (20 mg triamcinolone acetonide for LHBT and supraspinatus tendons)
Number of subjects: 60
Study 33338463 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 60
Study 35179585 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor prognostic understanding regarding life expectancy estimates
Number of subjects: 541
Study 35179585 — intervention group
Group type: EXPERIMENTAL
Intervention: Discordance regarding life expectancy estimates
Number of subjects: 541
Study 33476068 — intervention group
Group type: EXPERIMENTAL
Intervention: SHAPE-NVL
Number of subjects: 88
Study 33476068 — intervention group
Group type: COMPARATOR
Intervention: VYC-20L
Number of subjects: 88
Study 35697559 — intervention group
Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Number of subjects: 240
Study 35697559 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 240
Study 33589279 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended oral antibiotic prophylaxis for 7 days after discharge
Number of subjects: 3855
Study 33589279 — intervention group
Group type: COMPARATOR
Intervention: No extended oral antibiotic prophylaxis
Number of subjects: 3855
Study 32909059 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise (RES)
Number of subjects: 12
Study 32909059 — intervention group
Group type: COMPARATOR
Intervention: Combined exercise (COMB: RES + AER)
Number of subjects: 12
Study 32909059 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (AER)
Number of subjects: 12
Study 32909059 — intervention group
Group type: COMPARATOR
Intervention: All exercise sessions (AER, RES, COMB)
Number of subjects: 12
Study 35529777 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 109
Study 35529777 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 109
Study 35529777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (COMB)
Number of subjects: 109
Study 35529777 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 109
Study 34244787 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Coaching for Mood and Weight (I‐CARE)
Number of subjects: 0